Loading asset research
Nuvation Bio Inc. Class A Common Stock
NUVBNYSE · USD · StocksQuote as of · Exchange session not verified$6.07
-3.42%
Today
NUVB
Loading 1D prices…
Market cap
$2.1B
Volume
4.3M
52w high
$9.7552w low
$2.99Company profile
Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
NYSE
Display currency
USD
Location
New York, NY, United States
Employees
305
Fiscal year end
1231
CIK
1811063
Session & valuation
Open$6.36
Previous close$6.28
Day high$6.39
Day low$5.95
30-day avg. volume5.2M
Outstanding shares351.1M
Diluted EPS-$0.60
Latest annual period
P/E (trailing)-10.11
P/E (forward)-404.67
Price / book8.36
Beta1.53
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc Ordinary Shares | $2.1B | $283.1M | +101.46% | $2.07 | -0.09% | Buy |
| SRPTSarepta Therapeutics Inc. Common Stock (DE) | $2.2B | $1.9B | -38.27% | -$7.13 | -0.29% | Hold |
| PVLAPalvella Therapeutics Inc. Common Stock | $2.2B | $0.00 | — | -$3.71 | -0.17% | Buy |
| RAPPRapport Therapeutics Inc. Common Stock | $2.1B | $0.00 | — | -$2.86 | +0.69% | Buy |
| BHCBausch Health Companies Inc. Common Stock | $2.2B | $10.3B | +1.53% | $0.42 | -3.46% | Hold |